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ABSTRACT
The Pathway Interaction Database (PID, http://pid.
nci.nih.gov) is a freely available collection of curated
and peer-reviewed pathways composed of human
molecular signaling and regulatory events and
key cellular processes. Created in a collaboration
between the US National Cancer Institute and
Nature Publishing Group, the database serves as a
research tool for the cancer research community
and others interested in cellular pathways, such as
neuroscientists, developmental biologists and
immunologists. PID offers a range of search fea-
tures to facilitate pathway exploration. Users can
browse the predefined set of pathways or create
interaction network maps centered on a single
molecule or cellular process of interest. In addition,
the batch query tool allows users to upload long
list(s) of molecules, such as those derived from
microarray experiments, and either overlay these
molecules onto predefined pathways or visualize
the complete molecular connectivity map. Users
can also download molecule lists, citation lists and
complete database content in extensible markup
language (XML) and Biological Pathways Exchange
(BioPAX) Level 2 format. The database is updated
with new pathway content every month and supple-
mented by specially commissioned articles on the
practical uses of other relevant online tools.
INTRODUCTION
The Pathway Interaction Database (PID, http://pid.nci.
nih.gov) is a growing collection of human signaling and
regulatory pathways curated from peer-reviewed literature
and stored in a computable format. PID was designed to
deal with two issues aﬀecting the representation of biolog-
ical processes: the arbitrariness of pathway boundaries
and the need to capture knowledge at diﬀerent levels
of detail. Pathway boundaries are often arbitrary and
overlapping: diﬀerent biologists might include diﬀerent
biochemical interactions in, for example, ‘the p53 signal-
ing pathway’; and it is not unusual for two pathways
representing distinct processes to have one or more inter-
actions in common. This fuzziness simply reﬂects the fact
that terms like ‘the p53 signaling pathway’ and ‘the BCR
signaling pathway’ are high-level concepts of convenience,
designating slices through the very complex mix of con-
current processes in the cell. An important goal of PID is
to provide an operational deﬁnition of high-level concepts
like ‘the BCR signaling pathway’ (Figure 1) in the form of
predeﬁned pathways, while at the same time allowing a
user to explore novel networks composed computationally
from the universe of interactions underlying the predeﬁned
pathways. Current knowledge of the components of any
given biological process is uneven. For example, for some
protein interactants the precise posttranslational modiﬁca-
tions might be known, while for other interactants perhaps
the only sure knowledge is that the protein is ‘active’. PID
provides descriptive mechanisms to cover both of these
cases. The ability to represent information at diﬀerent
levels of detail is also useful in communicating generaliza-
tions. For example, it is sometimes useful to encapsulate a
complex process, such as cytoskeleton reorganization as a
single event or to treat as a single entity a set of proteins,
such as Class 1A PI3Ks that are functionally equivalent in
catalyzing a given event. PID has mechanisms for dealing
with incomplete knowledge, for encapsulating complex
events and for expressing generalizations.
PID has adopted a network-level representation, similar
to Reactome (1), HumanCyc (2) and KEGG (3). Like
Reactome and HumanCyc, PID annotates interactions
with citations to the literature. PID diﬀers from
Reactome, HumanCyc and KEGG in its focus on signal-
ing and regulatory pathways; it does not attempt to cover
metabolic processes or generic mechanisms like transcrip-
tion and translation (see Table 1 for a comparison of PID
with other publicly accessible pathway databases). PID
contains only structured data and it links to but does
not reproduce molecular information readily available
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The principal source of data in PID is the highly curated
‘NCI-Nature Curated’ collection of pathways, but PID
also includes two other sources of data: data imported
into the PID data model from Reactome’s Biological
Pathways Exchange (BioPAX) Level 2 (4) export, and
an import of information from the BioCarta collection
of pathways (Table 2). All data in PID is freely available,
without restriction on use. Bulk downloads are available
in BioPAX Level 2, a standard format for exchanging
pathway information, and a PID-speciﬁc XML format
at http://pid.nci.nih.gov/PID/download.shtml.
DATA MODEL
In PID, an interaction is an event with its participating
molecules and conditions. A PID pathway is a network of
these events connected by the participant molecules. PID
recognizes four kinds of molecules: small molecules (called
compounds), RNA, proteins and complexes. PID recog-
nizes ﬁve kinds of events: gene regulation (called transcri-
ption, but encompassing both transcription and
translation), molecule transport (called translocation),
small-molecule conversion (called reaction), protein–
protein interactions (called modiﬁcation) and black-box
processes whose internal composition is not provided
(called macroprocesses). In addition, an entire pathway
can be abstracted and used as a single event in another
pathway. As a participant in an event, a molecule may
have one of four roles: input, output, positive regulator
and negative regulator. These roles deﬁne simple relations:
an interaction consumes its inputs (but not its regulators)
and produces its outputs; and the inputs, positive regula-
tors and the absence of negative regulators are jointly the
necessary and suﬃcient causes of the interaction.
Each molecule in PID has a deﬁning entity, called a
basic molecule. Basic molecules are distinguished by
their nucleotide or amino acid sequence (for macromole-
cules) or by their chemical formula (for small molecules).
While PID does not record the sequence of a macromole-
cule or the chemical formula for a small molecule, each
protein or RNA is associated with a UniProt or Entrez
Gene accession and most small molecules are associated
with Chemical Abstracts Service (CAS) registry numbers.
A basic molecule has a primary name and may have multi-
ple aliases. Each molecule use, as an interactant in an
interaction or as a component of a complex, references
its corresponding basic molecule. Each molecule use may
have additional information, including posttranslational
modiﬁcations (for proteins) and cellular location and
activity state (for all molecule types).
A basic protein molecule has a single identifying
UniProt accession associated with a particular amino
acid sequence. If the particular isoform of a protein used
in an interaction is not known, then the basic protein mole-
cule may be associated with an Entrez Gene identiﬁer
instead of a UniProt accession; in PID, this method of
identifyingproteinsisrestrictedalmostentirelytotheuncu-
rated section of the database imported from BioCarta.
Figure 1. BCR signaling pathway. The pathway header information includes the date of the latest revision; the data curation or import source; the
curator; the reviewers; the stable pathway identiﬁer; links to a pathway-speciﬁc molecule list and a pathway-speciﬁc references list; and links to
pathway graphic and text data exchange format options.
Nucleic Acids Research, 2009,Vol. 37,Database issue D675A use of a protein as a participant in an interaction or
component of a complex may have additional attributes:
posttranslational modiﬁcations, an abstract activity-state
attribute and a cellular location attribute. Currently, PID
uses 13 types of posttranslational modiﬁcations, with
phosphorylation being by far the most frequently used
modiﬁcation (Table 3). The abstract activity-state attri-
bute, with values such as ‘active’ and ‘inactive’, allows
curators to distinguish functionally diﬀerent forms of a
protein even if the precise covalent modiﬁcations are not
known. Values for the cellular location attribute are
drawn from the Gene Ontology (GO) cellular component
vocabulary (5). Cleaved subunits of a precursor protein
are not distinguished by the posttranslational modiﬁca-
tion mechanism; rather they are treated as basic protein
molecules separate from each other and from the precur-
sor. However, PID explicitly relates the cleaved subunit
to its precursor and records the cleavage coordinates
when these are known. A PID protein corresponds
roughly to a BioPAX Level 3 protein reference, while a
BioPAX Level 3 protein corresponds to a PID protein
use (with posttranslational modiﬁcations and cellular
location).
PID allows the deﬁnition of generic proteins, com-
plexes, small molecules and RNA molecules. A generic
molecule is called a family, but is not restricted to the
traditional protein families deﬁned by sequence similarity:
any set of proteins (or other type of molecule) that are in
some respect functionally equivalent may be grouped in a
family. Individual protein members of a protein family
may have posttranslational modiﬁcations or activity
states. The family itself can be used as a participant in
an interaction, or as a component of a complex.
Because data are entered by multiple curators and
because the database contains data from multiple sources,
PID needs rules for determining equivalence of molecules.
Two basic molecules that are neither families nor com-
plexes are equivalent if they have the same external data-
base accession (e.g. UniProt or Entrez Gene), or if, in
cases where neither has an external database accession,
they have the same name. Two molecule uses (as partici-
pant in an interaction or component of a complex or
member of a family) are equivalent if they refer to the
same basic molecule, and have the same (or no) posttran-
slational modiﬁcations, and have the same (or no)
activity-state attribute, and have the same (or no) cellular
location attribute. Two basic families (or complexes) are
equivalent, if they have the same number of members (or
components) and if for each member (component) of one,
there is an equivalent member (component) in the other.
These rules are applied recursively to deﬁne, for example,
equivalent uses of complexes with components that are
families. Equivalence of molecule uses is the basis on
which novel networks are constructed: any two interac-
tions in the database may be joined in a network if one
interaction has a participant that is equivalent to a parti-
cipant in the other interaction. Analogous rules of equiva-
lence are implemented for interactions and entire
networks, allowing equivalent (redundant) interactions
to be pruned from the novel networks.
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D676 Nucleic Acids Research, 2009, Vol. 37, DatabaseissueAn interaction may be supported by one or more
citations to the literature. Currently, interactions in the
NCI-Nature Curated data source are annotated with
3105 distinct PubMed references. In addition, an interac-
tion may be annotated with one or more evidence codes
that specify the kind of evidence adduced in the citations
in support of the interaction (Table 4).
A predeﬁned pathway is a curated pathway representing
a known biological process. At present, every pathway
stored in the PID database is a predeﬁned pathway and
every interaction in the database is a member of at least
one predeﬁned pathway. However, the search and retriev-
al tools allow the user to compose novel pathways from
interactions deﬁned in the predeﬁned pathways. This abil-
ity to recombine interactions and to thus create novel
pathways is a distinguishing feature of PID.
Since the original BioCarta diagrams were not asso-
ciated with an explicit data model, the import of the
BioCarta pathway data did not challenge the PID data
model. The original BioCarta diagrams show protein–
protein interactions, but the semantics of the connecting
arrows are implicit. The import of these pathways into
PID required the interpretation of each interaction and
the manual encoding of the semantics in the PID data
model. This was tedious, but since the original BioCarta
pathways were underspeciﬁed, the process did not entail
loss of information. In contrast, the import of the
Reactome data is automated but does entail some loss
of information. PID uses Reactome’s BioPAX export as
the source for the imported Reactome data. Some features
of Reactome are not expressible in BioPAX Level 2.
For example, Reactome has ‘entity sets’, which corre-
spond roughly to PID’s molecule families. However,
since BioPAX Level 2 lacks the means to specify an
entity set, this information was lost in the import process.
Along with other important enhancements, this is being
corrected in BioPAX Level 3. On the other hand,
Reactome has some features that are expressible in
BioPAX Level 2 but have no correspondence in PID.
For example, in Reactome it is possible to explicitly spe-
cify that one interaction is a predecessor (‘preceding
event’) of another, and this is also directly expressible in
BioPAX Level 2. However, in PID the predecessor rela-
tion is implicit, inferred from the identity of interactants
and the directionality of inputs and outputs. Con-
sequently, the predecessor relation between two Reactome
interactions that do not share an interactant is lost in the
PID import.
DATA CURATION
Nature Publishing Group (NPG) editors create the NCI-
Nature Curated pathways. Pathways selected for curation
are based on potential drug targets, suggestions made by
users and reviewers, and other molecules known to be of
interest to the cell signaling community. A list of NCI-
Nature Curated pathways, along with a list of the path-
ways imported from Reactome and BioCarta, can be
found on the Browse pathways page of the PID website:
http://pid.nci.nih.gov/browse_pathways.shtml
In curating, editors synthesize meaningful networks of
events into deﬁned pathways and adhere to the PID data
model for consistency in data representation: molecules
and biological processes are annotated with standardized
names and unambiguous identiﬁers; and signaling and
regulatory events are annotated with evidence codes and
references. To ensure accurate data representation, editors
assemble pathways from data that is principally derived
from primary research publications. The majority of data
in PID is human; however, if a ﬁnding discovered in
another mammal is also deemed to occur in humans, edi-
tors may decide to include this ﬁnding, but will also record
that the evidence was inferred from another species. Prior
to publication, all pathways are reviewed by one or more
experts in a ﬁeld for accuracy and completeness.
Table 4. Evidence in NCI-Nature Curated data source
Code Evidence kind Uses
IAE Inferred from array experiments 3
IDA Inferred from direct assay 1780
IEP Inferred from expression pattern 37
IFC Inferred from functional complementation 13
IGI Inferred from genetic interaction 12
IMP Inferred from mutant phenotype 1689
IOS Inferred from other species 1139
IPI Inferred from physical interaction 1203
RGE Inferred from reporter gene expression 311
Table 2. Summary of all data sources
NCI-Nature
Curated
Reactome
imported
BioCarta
imported
Pathways 77 63 254
Subpathways 42 753 0
Interactions 4373 3466 3003
Proteins 2607 2692 4218
Small molecules 135 617 205
Complexes 1949 1897 880
Table 3. Posttranslational modiﬁcations in NIC-Nature Curated data
source
Modiﬁcation type All uses Unique
modiﬁcations
Acetylation 111 46
Farnesylation 7 4
Geranylgeranylation 2 2
Glycosaminoglycan 9 2
Glycosylation 135 15
Hydroxylation 13 3
Methylation 13 2
Myristoylation 15 4
Oxidation 8 4
Palmitoylation 52 14
Phosphorylation 7403 1070
Sumoylation 50 10
Ubiquitination 149 52
Nucleic Acids Research, 2009,Vol. 37,Database issue D677Any pathway curation eﬀort must decide to what extent
to annotate pathways and interactions with information
about the larger biological context, including the cell types
in which a set of interactions is known to occur and the
role of individual pathways in speciﬁc pathologies. Using
the GO biological process vocabulary, PID curators are
able to connect interactants and interactions to macropro-
cesses that characterize particular cell types (e.g. ‘endothe-
lial cell migration’). While, it would be desirable to
annotate each interaction with the list of cell types in
which the interaction has been observed, PID does not
at present attempt to supply this level of detail. Given
the sparseness of available data, it would be necessary to
specify not only positive ﬁndings but also negative ﬁnd-
ings in order to prevent a lack of data from being misin-
terpreted as the absence of the interaction in a particular
cell type. PID has a few pathways that explicitly describe a
particular pathological response (e.g. ‘Cellular roles of
anthrax toxin’); however, the focus of PID is normal
human biology. The assumption is that a ‘pathological
pathway’ relies on the signaling topology of normal biol-
ogy but deviates from normal biology in quantity (e.g.
overabundance of a protein), in co-occurrence (abnormal
presence of two reactants at the same time in the same
cellular compartment), or in the introduction of speciﬁc
abnormal reactants (e.g. the anthrax toxin or the consti-
tutively active BCR/ABL fusion protein). Curators are
able to specify abnormal reactants; however, this feature
has not been used extensively to date. As described in the
next section, an important use of the batch query is for a
researcher to overlay experimental information about
such deviations onto the normal signaling topology and
thus visualize possible perturbations.
WEB INTERFACE AND APPLICATION
PID provides several query options: a simple query, an
advanced query, a connected molecules query and a
batch query. In the simple query, the user provides the
name, alias or accession of a molecule or biological pro-
cess; wildcarding is permitted. The query will return a list
of all uses of the molecule, as simplex or as participant in a
complex, and all uses of the biological process, in the
database, with hyperlinks to visualizations of the relevant
predeﬁned pathways containing the queried entities. The
user also has the option to visualize the novel network(s)
that include all interactions using the queried entities. The
advanced query allows the user to construct the set of
novel networks from interactions that: (i) involve any of
a set of user-speciﬁed molecules, or (ii) are part of any
predeﬁned pathway whose name includes a user-speciﬁed
key word, or (iii) have a user-speciﬁed GO biological pro-
cess term or National Cancer Institute (NCI) Thesaurus
(6) term as their event type or condition. An important
feature of the advanced query is the provision for includ-
ing interactions that are immediately upstream or down-
stream of the set of interactions retrieved by molecule,
pathway name or GO/NCI Thesaurus term. The con-
nected molecules query allows a user to ﬁnd a novel net-
work that connects two or more molecules speciﬁed by
name, alias or accession. The query will ﬁnd only one of
the possibly many networks satisfying the constraint, but
the one found will have the minimum number of interac-
tions. Finally, the batch query allows a user to upload one
or two lists of molecule identiﬁers (name, alias or acces-
sion). The user has two options: to analyze the number of
molecules in the lists that ‘hit’ each predeﬁned pathway or
to construct the novel network(s) that include all interac-
tions using any of the listed molecules. For the ﬁrst
option, the query uses a hypergeometric distribution to
compute the probability that each pathway in the data-
base is hit by molecules in either of the lists. The query
returns a list of pathways ordered by P-value. In the visua-
lization of a predeﬁned pathway (ﬁrst option) or novel
pathway (second option), molecules from the ﬁrst list
are colored blue, molecules from the second list are
colored red and any molecules appearing in both lists
are colored purple. Supplementary Figure 1 presents an
example of invoking the batch query with a single mole-
cule list, the 120 protein kinases found by Greenman et al.
(7) to have at least one cancer-predisposing mutation.
Selecting the predeﬁned pathways option, one can see
that this list samples a small number of pathways,
biased toward immune cell signaling, at a P<0.0001.
While PID associates a single external database acces-
sion (typically a UniProt accession) with a protein, the
query interface searches PID not only by UniProt acces-
sion, but also by related gene identiﬁers (HUGO symbol,
alias, Entrez Gene identiﬁer). Any predeﬁned pathway or
novel network can be visualized in either GIF (graphics
interchange format) or SVG (scalable vector graphics)
graphic mode. Network graphics are all automatically
constructed from the underlying data using the
GraphViz package (8). Events and molecule uses in the
graphics are hyperlinked to HTML pages of information
about the interaction or molecule. In addition, any prede-
ﬁned pathway or novel network can be exported in native
PID XML or BioPAX Level 2 formats. Using the BioPAX
export, a user can also visualize PID pathways in
Cytoscape (http://cytoscape.org) a popular third-party
network visualization tool (9). For any predeﬁned path-
way, the user can obtain (and export to tab-separated
format) a list of literature citations and participating
molecules.
DISCUSSION AND FUTURE DIRECTIONS
PID is a highly structured, curated database of molecular
interactions and events that compose human cell signaling
and regulatory pathways. A particular strength of PID is
the ability to create novel networks that can reveal parallel
alternative paths to events of interest, like activation of a
protein or disassembly of a complex in the DNA repair
process. In cancer biology, such a view can elucidate the
variety of strategies that a given type of cancer may adopt,
explain why a single-agent therapy is not eﬀective and
suggest potential multi-agent therapies. Increasingly,
molecular networks are recognized as frameworks for
integrating and interpreting experimental data. For exam-
ple, by using pathways as the integrating framework,
D678 Nucleic Acids Research, 2009, Vol. 37, Databaseissuethe Cancer Genome Atlas project has mapped genomic
abnormalities of diﬀerent types—copy number, mutation
and methylation—to a set of oncogenic processes (10). At
present, most attempts to proﬁle tumor subtypes have
relied on DNA and RNA assays. However, as high-
throughput proteomic methods improve the kind of
detailed information on posttranslational modiﬁcations
of proteins available in PID will be essential in mapping
more accurately the state of a cell.
Consistent with its focus on interactions and events
derived from curated signaling cascades and regulatory
processes, PID does not at present include interaction
data deriving from high-throughput protein–protein inter-
action experiments. This reﬂects not a judgment on the
quality of high-throughput data, but a recognition that
there are databases speciﬁcally designed to provide access
to this data (11, 12, 13). However, while it does not lead
directly to the construction of signaling cascades, informa-
tion from high-throughput protein–protein interaction
experiments can be useful in interpreting the curated path-
ways and assessing their completeness. For example, a
high-throughput protein–protein interaction experiment
can identify an unexpected binding partner for a catalyst,
suggesting the possibility that the in vivo presence of the
partner can sequester the catalyst and thus turn oﬀ down-
stream interactions. In the future, PID will allow users to
take advantage of high-throughput protein–protein inter-
action data, either by allowing users to upload interaction
sets to be added to the novel networks created by PID
queries or by querying other data sources (such as
Pathway Commons, http://pathwaycommons.org) as
needed to support a user query. The PID data model is
currently being integrated with NCI’s Cancer Bioinfor-
matics Infrastructure Objects model (caBIO) (14), thereby
making PID data accessible on NCI’s caGrid (15).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
The National Cancer Institute. Funding for open access
charge: National Cancer Institute.
Conﬂict of interest statement. None declared.
REFERENCES
1. Vastrik,I., D’Eustachio,P., Schmidt,E., Joshi-Tope,G., Gopinath,G.,
Croft,D., de Bono,B., Gillespie,M., Jassal,B., Lewis,S. et al. (2007)
Reactome: a knowledge base of biologic pathways and processes.
Genome Biol., 8, R39.
2. Romero,P., Wagg,J., Green,M.L., Kaiser,D., Krummenacker,M.
and Karp,P.D. (2005) Computational prediction of human
metabolic pathways from the complete human genome.
Genome Biol., 6, R2.
3. Kanehisa,M., Araki,M., Goto,S., Hattori,M., Hirakawa,M.,
Itoh,M., Katayama,T., Kawashima,S., Okuda,S., Tokimatsu,T.
et al. (2008) KEGG for linking genomes to life and the
environment. Nucleic Acids Res., 36, D480–D484.
4. Bader,G.D., Cary,M. and Sander,C. (2006) BioPAX – Biological
Pathway Data Exchange Format. Encyclopedia of Genomics,
Proteomics and Bioinformatics. John Wiley & Sons, Ltd, New York.
5. Ashburner,M., Ball,C.A., Blake,J.A., Botstein,D., Butler,H.,
Cherry,J.M., Davis,A.P., Dolinski,K., Dwight,S.S., Eppig,J.T. et al.
(2000) Gene ontology: tool for the uniﬁcation of biology. The Gene
Ontology Consortium. Nat. Genet., 25, 25–29.
6. Fragoso,G., de Coronado,S., Haber,M., Hartel,F. and Wright,L.
(2004) Overview and utilization of the NCI thesaurus. Comp. Funct.
Genomics, 5, 648–654.
7. Greenman,C., Stephens,P., Smith,R., Dalgliesh,G.L., Hunter,C.,
Bignell,G., Davies,H., Teague,J., Butler,A., Stevens,C. et al. (2007)
Patterns of somatic mutation in human cancer genomes. Nature,
446, 153–158.
8. Gansner,E.R. and North,S.C. (1999) An open graph visualization
system and its applications. Software Pract. Exper. (S1), 1–5
9. Cline,M.S., Smoot,M., Cerami,E., Kuchinsky,A., Landys,N.,
Workman,C., Christmas,R., Avila-Campilo,I., Creech,M., Gross,B.
et al. (2007) Integration of biological networks and gene expression
data using Cytoscape. Nat. Protoc., 2, 2366–2382.
10. The Cancer Genome Atlas Research Network (2008)
Comprehensive genomic characterization deﬁnes human glioblas-
toma genes and core pathways. Nature, 4 September 2008
[Epub ahead of print].
11. Chatr-aryamontri,A., Ceol,A., Palazzi,L.M., Nardelli,G.,
Schneider,M.V., Castagnoli,L. and Cesareni,G., (2007)
MINT: the Molecular INTeraction database. Nucleic Acid Res., 35,
D572–D574.
12. Hermjakob,H., Montecchi-Palazzi,L., Lewington,C., Mudali,S.,
Kerrien,S, Orchard,S., Vingron,M., Roechert,J, Wood,V. et al.
(2004) IntAct: an open source molecular interaction database..
Nucleic Acid Res., 32, D452–D455.
13. Breitkreutz,B.J., Stark,C., Reguly,T., Boucher,L., Breitkreutz,A.,
Livstone,M., Oughtred,R., Lackner,D.H., Bahler,J., Wood,V. et al.
(2008) The BioGRID interaction database: 2008 update. Nucleic
Acids Res., 36, D637–D640.
14. Covitz,P.A., Hartel,F., Schaefer,C., De Coronado,S., Fragoso,G.,
Sahni,H., Gustafson,S. and Buetow,K.H. (2003) caCORE: a
common infrastructure for cancer informatics. Bioinformatics, 19,
2404–2412.
15. Oster,S., Langella,S., Hastings,S., Ervin,D., Madduri,R., Phillips,J.,
Kurc,T., Siebenlist,F., Covitz,P., Shanbhag,K. et al. (2008)
caGrid 1.0: an enterprise Grid infrastructure for biomedical
research. J. Am. Med. Inform. Assoc., 15, 138–149.
Nucleic Acids Research, 2009,Vol. 37,Database issue D679